OrbiMed’s Morphic Holding, Inc. Common Stock MORF Stock Holding History

OrbiMed’s Portfolio MORF Stock Details MORF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-612,500	Closed	-$20.9M	–	135
2024 Q2	$20.9M	Buy	612,500 +54,000	+10%	+$1.6M	0.41%	59
2024 Q1	$19.7M	Buy	558,500 +285,100	+104%	+$9.56M	0.36%	65
2023 Q4	$7.9M	Buy	273,400 +64,900	+31%	+$1.55M	0.16%	83
2023 Q3	$4.78M	Hold	208,500	–	–	0.1%	100
2023 Q2	$12M	Buy	+208,500	New	+$10.9M	0.22%	82

Other funds holding MORF

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Hoey Investments Coatesville, Pennsylvania $693M AUM 34.99% 1-Year Est. Return

OrbiMed's MORF Position: Q3 2024 in Review

OrbiMed sold out of Morphic Holding, Inc. Common Stock (MORF) in Q3 2024, closing a stake of 612,500 shares — an estimated $20.9M sold.

OrbiMed first reported a position in MORF in Q2 2023 and held it in 5 quarters. The position peaked at $20.9M in Q2 2024. 2 funds tracked by Wall St. Rank hold MORF as of Q3 2024.

OrbiMed reported no remaining Morphic Holding, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
OrbiMed sold 612,500 Morphic Holding, Inc. Common Stock shares in Q3 2024, an estimated $20.9M.
OrbiMed first reported a position in Morphic Holding, Inc. Common Stock in Q2 2023 and held it in 5 quarters.
OrbiMed's Morphic Holding, Inc. Common Stock position peaked at $20.9M in Q2 2024.
2 funds tracked by Wall St. Rank held Morphic Holding, Inc. Common Stock as of Q3 2024.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.